Know Cancer

or
forgot password

The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Male
Prostatic Neoplasms

Thank you

Trial Information

The Role of MRI Perfusion to Detect Locally Recurrent or Persistent Disease in Prostate Carcinoma Treated With Radiation Therapy - A Pilot Study


Inclusion Criteria:



- Previously have had radical radiotherapy for localised prostate cancer

- Due to undergo routine post-treatment prostatic biopsies

- Suitable for MRI scan

- Adequate renal function

- No previous reaction to gadolinium

- Able to give informed consent

- No recent prostate biopsy within 6 weeks of enrolment

- Performance status (Eastern Cooperative Oncology Group [ECOG]) 0 or 1

Exclusion Criteria:

- Not suitable for MRI scan

- Previous reaction to gadolinium

- Impaired renal function

- Inability to give informed consent

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine whether there may be a role for MRI perfusion in the detection of recurrent or persistent prostatic cancer after previous radiotherapy

Principal Investigator

Michael Milosevic, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Princess Margaret Hospital, Canada

Authority:

Canada: Ethics Review Committee

Study ID:

UHN REB 03-0272-CE

NCT ID:

NCT00230386

Start Date:

May 2003

Completion Date:

Related Keywords:

  • Prostatic Neoplasms
  • Neoplasms
  • Carcinoma
  • Prostatic Neoplasms

Name

Location